{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:12:16Z","timestamp":1792314736516,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.breast.2017.05.001","type":"journal-article","created":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T16:15:19Z","timestamp":1494864919000},"page":"65-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Impact of 2013 ASCO\/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH"],"prefix":"10.1016","volume":"34","author":[{"given":"M.","family":"Ragazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bisagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bassano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Tamagnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Foroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bortesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Falco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Braglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Savoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bologna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Di Cicilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bisagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2017.05.001_bib1","unstructured":"Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO classification of tumours of the breast. 2012."},{"issue":"31","key":"10.1016\/j.breast.2017.05.001_bib2","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.breast.2017.05.001_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1634\/theoncologist.7-suppl_4-2","article-title":"Why the epidermal growth factor receptor? The rationale for cancer therapy","volume":"7","author":"Baselga","year":"2002","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.breast.2017.05.001_bib4","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"4785","key":"10.1016\/j.breast.2017.05.001_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.breast.2017.05.001_bib6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer","volume":"354","author":"Joensuu","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.breast.2017.05.001_bib7","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.breast.2017.05.001_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.breast.2017.05.001_bib9","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.2003.02.018","article-title":"Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm","volume":"21","author":"Burstein","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.breast.2017.05.001_bib10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.breast.2017.05.001_bib11","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMc0801440","article-title":"HER2 status and benefit from adjuvant trastuzumab in breast cancer","volume":"358","author":"Paik","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.breast.2017.05.001_bib12","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","article-title":"Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31","volume":"29","author":"Perez","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.breast.2017.05.001_bib13","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.breast.2017.05.001_bib14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/jcp.53.5.374","article-title":"Laboratory assessment of the status of Her-2\/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays","volume":"53","author":"Wang","year":"2000","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.breast.2017.05.001_bib15","unstructured":"http:\/\/www.fda.gov\/Drugs\/default. U.S. Food and Drug Administration: Drugs. In."},{"issue":"1","key":"10.1016\/j.breast.2017.05.001_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.breast.2017.05.001_bib17","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1200\/JCO.2013.53.9213","article-title":"Interpretation of human epidermal growth factor receptor 2 (HER2) in situ hybridization assays using 2013 update of American Society of Clinical Oncology\/College of American Pathologists HER2 Guidelines","volume":"32","author":"Bhargava","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2017.05.001_bib18","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/his.12357","article-title":"The updated ASCO\/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice","volume":"64","author":"Rakha","year":"2014","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.breast.2017.05.001_bib19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/path.2574","article-title":"Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis","volume":"219","author":"Marchio","year":"2009","journal-title":"J\u00a0Pathol"},{"issue":"2","key":"10.1016\/j.breast.2017.05.001_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1309\/AJCPE5NCHWPSMR5D","article-title":"Impact of the 2013 ASCO\/CAP HER2 guideline updates at an academic medical center that performs primary HER2 FISH testing: increase in equivocal results and utility of reflex immunohistochemistry","volume":"144","author":"Muller","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"10.1016\/j.breast.2017.05.001_bib21","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/his.12723","volume":"67","author":"Bethune","year":"2015","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.breast.2017.05.001_bib22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1309\/AJCP3Q9WFOQTKUVV","article-title":"The new equivocal: changes to HER2 FISH results when applying the 2013 ASCO\/CAP guidelines","volume":"144","author":"Long","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"10.1016\/j.breast.2017.05.001_bib23","doi-asserted-by":"crossref","first-page":"e0140652","DOI":"10.1371\/journal.pone.0140652","article-title":"Impact of modified 2013 ASCO\/CAP guidelines on HER2 testing in breast cancer. One year experience","volume":"10","author":"Varga","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.breast.2017.05.001_bib24","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1634\/theoncologist.2014-0195","article-title":"Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method","volume":"19","author":"Sapino","year":"2014","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.breast.2017.05.001_bib25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.prp.2014.09.010","article-title":"Comparison of the 2007 and 2013 ASCO\/CAP evaluation systems for HER2 amplification in breast cancer","volume":"211","author":"Pu","year":"2015","journal-title":"Pathol Res Pract"},{"issue":"3","key":"10.1016\/j.breast.2017.05.001_bib26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10549-016-3717-z","article-title":"HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO\/CAP practice guideline","volume":"155","author":"Fan","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2017.05.001_bib27","author":"Shah","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2017.05.001_bib28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10549-016-3824-x","volume":"157","author":"Singh","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.breast.2017.05.001_bib29","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/modpathol.2015.112","article-title":"Impact of updated HER2 testing guidelines in breast cancer\u2013re-evaluation of HERA trial fluorescence in situ hybridization data","volume":"28","author":"Stoss","year":"2015","journal-title":"Mod Pathol"},{"issue":"29","key":"10.1016\/j.breast.2017.05.001_bib30","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1038\/onc.2011.506","article-title":"Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA","volume":"31","author":"Paroni","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.breast.2017.05.001_bib31","unstructured":"Adamo V, Barone CAM, Bertetto O, Bevilacqua G, Biffi R, Bordonaro R, et\u00a0al. Consensus Workshop e Raccomandazioni sull 'impiego delle diverse metodiche per la determinazione dello stato di HER2 nel carcinoma mammario e nel carcinoma gastrico. In. http:\/\/www.siapec.it\/content\/file\/2785\/CP_Catania%20DEF.pdf 2010."},{"issue":"6","key":"10.1016\/j.breast.2017.05.001_bib32","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2015.62.1268","article-title":"Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase iii trial of paclitaxel plus trastuzumab with or without lapatinib","volume":"34","author":"Carey","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.breast.2017.05.001_bib33","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/jamaoncol.2016.0339","article-title":"Effects of estrogen receptor and human epidermal growth factor Receptor-2 levels on the efficacy of trastuzumab: a secondary analysis of the HERA trial","volume":"2","author":"Loi","year":"2016","journal-title":"JAMA Oncol"},{"issue":"9816","key":"10.1016\/j.breast.2017.05.001_bib34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial","volume":"379","author":"Baselga","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.breast.2017.05.001_bib35","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jnci\/95.2.142","article-title":"Quantitative association between HER-2\/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer","volume":"95","author":"Konecny","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2017.05.001_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.66.6693","article-title":"HER2 gene amplification testing by fluorescent in situ hybridization (FISH): comparison of the ASCO-college of american pathologists guidelines with FISH scores used for enrollment in breast cancer international research group clinical trials","author":"Press","year":"2016","journal-title":"J\u00a0Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977617304460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977617304460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:37:28Z","timestamp":1760776648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977617304460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":36,"alternative-id":["S0960977617304460"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2017.05.001","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of 2013 ASCO\/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2017.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}